SlideShare a Scribd company logo
Type 1 Diabetes
Presented by- DelveInsight Business Research
What is Type 1 Diabetes?
Diabetes is a chronic metabolic condition characterized by high or low blood glucose (or blood sugar) levels,
leading to significant damage to the heart, blood vessels, eyes, kidneys, and nerves over time. The rationale
behind developing diabetes incorporates two factors: insufficient insulin production (produced by the
pancreas and reduced blood glucose) or unsatisfactory cell response to insulin action.
Clinically, diabetes is classified into three types, type 1 diabetes (TD-1), Type 1 Diabetes (TD2),
and gestation diabetes. TD1 is the consequence of an autoimmune reaction that causes the
pancreas to suppress insulin-producing β-cells and leads to a severe insulin deficiency.
TD2 is linked with a genetic factor, which is far more common and substantially correlates
with obesity and unhealthy lifestyles. Insulin resistance (inadequate reaction of peripheral
cells to insulin) and pancreatic β-cell dysfunction (impaired insulin secretion) are marked by
Type 1 Diabetes, leading to relative insulin deficiency.
View– Type 1 Diabetes market insights
● The US
● EU5 (Germany, France, Italy, Spain,
and the United Kingdom)
● Japan
How Many Regions Are
Covered?
This segment of the report provides a brief
competitive analysis of Type 1 Diabetes, to
help understand the competition in the
market. It gives a comparative understanding
of the products based on types of wounds.
Type 1 diabetes is an autoimmune disorder, it is the most common type of diabetes
among children, and however, type 1 diabetes can occur at any age. The typical
symptoms of type 1 diabetes include excessive thirst, blurred vision, dry mouth,
upset stomach and vomiting, bedwetting, frequent urination, unexplained weight
loss, fatigue, labored breathing, lack of energy, and constant hunger. In patients
having extreme type 1 diabetes, the symptoms include fruity odor to the breath,
belly pain, and rapid breathing.
The cause of type 1 diabetes is unknown, however since it is an autoimmune
disorder, wherein the body mistakenly attacks the insulin-producing (islet, or islets of
Langerhans) cells in the pancreas, other causes include; genetics and exposure to
viruses and other environmental factors.
The diagnostic procedure to confirm type 1 diabetes includes Glycated hemoglobin
(A1C) test (> 6.5 on two separate tests, Random blood sugar test (> 200 mg/dL, along
with symptoms of diabetes), Fasting blood sugar test(> 126 mg/dL on two separate
tests). If the patient is diagnosed with diabetes, the doctor checks the presence of
autoantibodies using blood tests.
Focusing on the chronic and severe nature of type 1 diabetes and type 2 diabetes,
the treatment approach for them is quite comprehensive; regularization of glucose
metabolism (continuous use of insulin) and control of risk factors are the key
treatment targets for type 1 diabetes.
Also, read– Type 1 Diabetes treatment market
What is the Type 1 Diabetes Market
Report Scope?
● The report covers the descriptive overview of Type 1 Diabetes , explaining its causes, signs and symptoms,
pathophysiology, diagnosis and currently available therapies
● Comprehensive insight has been provided into the Type 1 Diabetes epidemiology and treatment in the 7MM
● Additionally, an all-inclusive account of both the current and emerging therapies for Type 1 Diabetes are
provided, along with the assessment of new therapies, which will have an impact on the current treatment
landscape
● A detailed review of Type 1 Diabetes market; historical and forecasted is included in the report, covering
drug outreach in the 7MM
● The report provides an edge while developing business strategies, by understanding trends shaping and
driving the global Type 1 Diabetes market
What are the Type 1 Diabetes Market
Report Highlights?
● In the coming years, Type 1 Diabetes market is set to change due to the rising awareness of the disease, and
incremental healthcare spending across the world; which would expand the size of the market to enable the
drug manufacturers to penetrate more into the market
● The companies and academics are working to assess challenges and seek opportunities that could influence
Type 1 Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve
the disease condition
● Major players are involved in developing therapies for Type 1 Diabetes . Launch of emerging therapies will
significantly impact the Type 1 Diabetes market
● A better understanding of disease pathogenesis will also contribute to the development of novel
therapeutics for Type 1 Diabetes
CREDITS: This presentation template was
created by Slidesgo, including icons by
Flaticon, and infographics & images by
Freepik
Please keep this slide for attribution
info@delveinsight.com
ybhardwaj@delveinsight.com
+91-9650213330
Do You Have Any Question or Query?
CREDITS: This presentation template was
created by Slidesgo, including icons by
Flaticon, and infographics & images by
Freepik
Thanks!

More Related Content

What's hot

Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
Ekta Patel
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
Almuataz Bellah Ahmad
 
Diabetes
DiabetesDiabetes
Diabetes
Sachin kumar
 
Diabetes mellitus
Diabetes  mellitusDiabetes  mellitus
Diabetes mellitus
ROMAN BAJRANG
 
Diabetes mellitus
Diabetes  mellitusDiabetes  mellitus
Diabetes mellitus
SushantLuitel1
 
TYPE 2 DIABETES IN CHILDREN AND ADOLESCENTS
TYPE 2 DIABETES IN CHILDREN AND ADOLESCENTSTYPE 2 DIABETES IN CHILDREN AND ADOLESCENTS
TYPE 2 DIABETES IN CHILDREN AND ADOLESCENTS
Apollo Hospitals
 
Diabetes mellitus an overview
Diabetes mellitus an overviewDiabetes mellitus an overview
Diabetes mellitus an overviewRuth Nwokoma
 
Diabetes mellitus overview and treatments
Diabetes mellitus overview and treatmentsDiabetes mellitus overview and treatments
Diabetes mellitus overview and treatments
Farzana Sultana
 
Diabetes
Diabetes Diabetes
Diabetes
Balaji Thorat
 
Diabetes Presentation
Diabetes PresentationDiabetes Presentation
Diabetes Presentation
MariaGHdz
 
Diabetes Mellitus (DM)
Diabetes Mellitus (DM)Diabetes Mellitus (DM)
Diabetes Mellitus (DM)
Abhay Rajpoot
 
Diabetes (Type 1)
Diabetes  (Type 1)Diabetes  (Type 1)
Diabetes (Type 1)
Dr. Deepika Kenjale
 
Pathophysiology of diabetes
Pathophysiology of diabetes Pathophysiology of diabetes
Pathophysiology of diabetes
SairamyaLibra
 
Type 1 diabetes powerpoint
Type 1 diabetes powerpointType 1 diabetes powerpoint
Type 1 diabetes powerpointhloiselle14
 
Diabetes
DiabetesDiabetes
Diabetes
Raymond Arhin
 
Diabetes
DiabetesDiabetes
Diabetes
DiabetesDiabetes
Diabetes
Sam Joe
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes
DiabetesDiabetes
Diabetes
DiabetesDiabetes
Diabetes
Dalia El-Shafei
 

What's hot (20)

Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes
DiabetesDiabetes
Diabetes
 
Diabetes mellitus
Diabetes  mellitusDiabetes  mellitus
Diabetes mellitus
 
Diabetes mellitus
Diabetes  mellitusDiabetes  mellitus
Diabetes mellitus
 
TYPE 2 DIABETES IN CHILDREN AND ADOLESCENTS
TYPE 2 DIABETES IN CHILDREN AND ADOLESCENTSTYPE 2 DIABETES IN CHILDREN AND ADOLESCENTS
TYPE 2 DIABETES IN CHILDREN AND ADOLESCENTS
 
Diabetes mellitus an overview
Diabetes mellitus an overviewDiabetes mellitus an overview
Diabetes mellitus an overview
 
Diabetes mellitus overview and treatments
Diabetes mellitus overview and treatmentsDiabetes mellitus overview and treatments
Diabetes mellitus overview and treatments
 
Diabetes
Diabetes Diabetes
Diabetes
 
Diabetes Presentation
Diabetes PresentationDiabetes Presentation
Diabetes Presentation
 
Diabetes Mellitus (DM)
Diabetes Mellitus (DM)Diabetes Mellitus (DM)
Diabetes Mellitus (DM)
 
Diabetes (Type 1)
Diabetes  (Type 1)Diabetes  (Type 1)
Diabetes (Type 1)
 
Pathophysiology of diabetes
Pathophysiology of diabetes Pathophysiology of diabetes
Pathophysiology of diabetes
 
Type 1 diabetes powerpoint
Type 1 diabetes powerpointType 1 diabetes powerpoint
Type 1 diabetes powerpoint
 
Diabetes
DiabetesDiabetes
Diabetes
 
Diabetes
DiabetesDiabetes
Diabetes
 
Diabetes
DiabetesDiabetes
Diabetes
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Diabetes
DiabetesDiabetes
Diabetes
 
Diabetes
DiabetesDiabetes
Diabetes
 

Similar to Type 1 diabetes ppt

DIABETIC.pdf
DIABETIC.pdfDIABETIC.pdf
DIABETIC.pdf
agyengo470
 
Oral hypogycemic agents
Oral hypogycemic agentsOral hypogycemic agents
Diabetes mellitus.pptx
Diabetes mellitus.pptxDiabetes mellitus.pptx
Diabetes mellitus.pptx
MohammedAbdela7
 
Understanding and Managing Diabetes A Comprehensive Guide.pdf
Understanding and Managing Diabetes A Comprehensive Guide.pdfUnderstanding and Managing Diabetes A Comprehensive Guide.pdf
Understanding and Managing Diabetes A Comprehensive Guide.pdf
CarlNell3
 
BETH MARTINSExplain the difference  between the types of dia.docx
BETH MARTINSExplain the difference  between the types of dia.docxBETH MARTINSExplain the difference  between the types of dia.docx
BETH MARTINSExplain the difference  between the types of dia.docx
tangyechloe
 
Advanced PharmacologyDiabetes is a group of metabolic diseas
Advanced PharmacologyDiabetes is a group of metabolic diseasAdvanced PharmacologyDiabetes is a group of metabolic diseas
Advanced PharmacologyDiabetes is a group of metabolic diseas
milissaccm
 
CAN DIABETES BE REVERSED?
CAN DIABETES BE REVERSED?CAN DIABETES BE REVERSED?
CAN DIABETES BE REVERSED?
ogheneromichael
 
Diabetes and Drug Treatments Essay.docx
Diabetes and Drug Treatments Essay.docxDiabetes and Drug Treatments Essay.docx
Diabetes and Drug Treatments Essay.docx
studywriters
 
Dm oral
Dm oralDm oral
Diabetes mellitus Type 1
Diabetes mellitus Type 1Diabetes mellitus Type 1
Diabetes mellitus Type 1
Diptarco Singha
 
Influence of systemic conditions on the periodontium
Influence of systemic conditions on the periodontiumInfluence of systemic conditions on the periodontium
Influence of systemic conditions on the periodontium
DR. OINAM MONICA DEVI
 
Diabetes at glance
Diabetes at glanceDiabetes at glance
Diabetes at glance
Rehab India Foundation
 
Diabetes: Get to know about it and its solution.
Diabetes: Get to know about it and its solution.Diabetes: Get to know about it and its solution.
Diabetes: Get to know about it and its solution.
Huma Kashif
 
Portfolio1
Portfolio1Portfolio1
Portfolio1asnyder9
 
Current Management of Diabetes Mellitus by Ghaza khan.
Current Management of Diabetes Mellitus by Ghaza khan.Current Management of Diabetes Mellitus by Ghaza khan.
Current Management of Diabetes Mellitus by Ghaza khan.
Ghaza Khan
 
Current management of Diabetes Mellitus by Ghaza khan.
Current management of Diabetes Mellitus by Ghaza khan.Current management of Diabetes Mellitus by Ghaza khan.
Current management of Diabetes Mellitus by Ghaza khan.
Ghaza Khan
 
Type 2 diabetes
Type 2 diabetesType 2 diabetes
Type 2 diabetesdamarizsz
 
Type 2 diabetes
Type 2 diabetesType 2 diabetes
Type 2 diabetes
CarlosKid14
 
General medicine update for every doctor
General medicine update for every doctorGeneral medicine update for every doctor
General medicine update for every doctor
DINESH and SONALEE
 

Similar to Type 1 diabetes ppt (20)

DIABETIC.pdf
DIABETIC.pdfDIABETIC.pdf
DIABETIC.pdf
 
Oral hypogycemic agents
Oral hypogycemic agentsOral hypogycemic agents
Oral hypogycemic agents
 
Diabetes mellitus.pptx
Diabetes mellitus.pptxDiabetes mellitus.pptx
Diabetes mellitus.pptx
 
Understanding and Managing Diabetes A Comprehensive Guide.pdf
Understanding and Managing Diabetes A Comprehensive Guide.pdfUnderstanding and Managing Diabetes A Comprehensive Guide.pdf
Understanding and Managing Diabetes A Comprehensive Guide.pdf
 
BETH MARTINSExplain the difference  between the types of dia.docx
BETH MARTINSExplain the difference  between the types of dia.docxBETH MARTINSExplain the difference  between the types of dia.docx
BETH MARTINSExplain the difference  between the types of dia.docx
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Advanced PharmacologyDiabetes is a group of metabolic diseas
Advanced PharmacologyDiabetes is a group of metabolic diseasAdvanced PharmacologyDiabetes is a group of metabolic diseas
Advanced PharmacologyDiabetes is a group of metabolic diseas
 
CAN DIABETES BE REVERSED?
CAN DIABETES BE REVERSED?CAN DIABETES BE REVERSED?
CAN DIABETES BE REVERSED?
 
Diabetes and Drug Treatments Essay.docx
Diabetes and Drug Treatments Essay.docxDiabetes and Drug Treatments Essay.docx
Diabetes and Drug Treatments Essay.docx
 
Dm oral
Dm oralDm oral
Dm oral
 
Diabetes mellitus Type 1
Diabetes mellitus Type 1Diabetes mellitus Type 1
Diabetes mellitus Type 1
 
Influence of systemic conditions on the periodontium
Influence of systemic conditions on the periodontiumInfluence of systemic conditions on the periodontium
Influence of systemic conditions on the periodontium
 
Diabetes at glance
Diabetes at glanceDiabetes at glance
Diabetes at glance
 
Diabetes: Get to know about it and its solution.
Diabetes: Get to know about it and its solution.Diabetes: Get to know about it and its solution.
Diabetes: Get to know about it and its solution.
 
Portfolio1
Portfolio1Portfolio1
Portfolio1
 
Current Management of Diabetes Mellitus by Ghaza khan.
Current Management of Diabetes Mellitus by Ghaza khan.Current Management of Diabetes Mellitus by Ghaza khan.
Current Management of Diabetes Mellitus by Ghaza khan.
 
Current management of Diabetes Mellitus by Ghaza khan.
Current management of Diabetes Mellitus by Ghaza khan.Current management of Diabetes Mellitus by Ghaza khan.
Current management of Diabetes Mellitus by Ghaza khan.
 
Type 2 diabetes
Type 2 diabetesType 2 diabetes
Type 2 diabetes
 
Type 2 diabetes
Type 2 diabetesType 2 diabetes
Type 2 diabetes
 
General medicine update for every doctor
General medicine update for every doctorGeneral medicine update for every doctor
General medicine update for every doctor
 

More from DelveInsight Business Research

BBXPB3422J_PARTB_2022-23 - Yashveer Bhardwaj.pdf
BBXPB3422J_PARTB_2022-23 - Yashveer Bhardwaj.pdfBBXPB3422J_PARTB_2022-23 - Yashveer Bhardwaj.pdf
BBXPB3422J_PARTB_2022-23 - Yashveer Bhardwaj.pdf
DelveInsight Business Research
 
BBXPB3422J_2022- Yashveer Bhardwaj.pdf
BBXPB3422J_2022- Yashveer Bhardwaj.pdfBBXPB3422J_2022- Yashveer Bhardwaj.pdf
BBXPB3422J_2022- Yashveer Bhardwaj.pdf
DelveInsight Business Research
 
Roche’s Glofitamab.pdf
Roche’s Glofitamab.pdfRoche’s Glofitamab.pdf
Roche’s Glofitamab.pdf
DelveInsight Business Research
 
Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/...
Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/...Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/...
Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/...
DelveInsight Business Research
 
Daiichi’s Patritumab.pdf
Daiichi’s Patritumab.pdfDaiichi’s Patritumab.pdf
Daiichi’s Patritumab.pdf
DelveInsight Business Research
 
Enhertu carving out a new space for itself in HER2 low patients
 Enhertu carving out a new space for itself in HER2 low patients Enhertu carving out a new space for itself in HER2 low patients
Enhertu carving out a new space for itself in HER2 low patients
DelveInsight Business Research
 
ASCO 2022 Conference.pdf
ASCO 2022 Conference.pdfASCO 2022 Conference.pdf
ASCO 2022 Conference.pdf
DelveInsight Business Research
 
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its prom...
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its prom...Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its prom...
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its prom...
DelveInsight Business Research
 
Vasomotor Symptoms Infographic PDF.pdf
Vasomotor Symptoms Infographic PDF.pdfVasomotor Symptoms Infographic PDF.pdf
Vasomotor Symptoms Infographic PDF.pdf
DelveInsight Business Research
 
Primary Hyperoxaluria
Primary HyperoxaluriaPrimary Hyperoxaluria
Primary Hyperoxaluria
DelveInsight Business Research
 
ASCO CONFERENCE.Making Way For Immunotherapy In The GI Cancers, Durvalumab To...
ASCO CONFERENCE.Making Way For Immunotherapy In The GI Cancers, Durvalumab To...ASCO CONFERENCE.Making Way For Immunotherapy In The GI Cancers, Durvalumab To...
ASCO CONFERENCE.Making Way For Immunotherapy In The GI Cancers, Durvalumab To...
DelveInsight Business Research
 
Chronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease MarketChronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease Market
DelveInsight Business Research
 
Is there enough opportunity in the competitive therapeutic landscape of Multi...
Is there enough opportunity in the competitive therapeutic landscape of Multi...Is there enough opportunity in the competitive therapeutic landscape of Multi...
Is there enough opportunity in the competitive therapeutic landscape of Multi...
DelveInsight Business Research
 
AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses ...
AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses ...AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses ...
AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses ...
DelveInsight Business Research
 
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post succes...
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post succes...Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post succes...
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post succes...
DelveInsight Business Research
 
What is the Multiple Sclerosis.pdf
What is the Multiple Sclerosis.pdfWhat is the Multiple Sclerosis.pdf
What is the Multiple Sclerosis.pdf
DelveInsight Business Research
 
Multiple Myeloma.pdf
Multiple Myeloma.pdfMultiple Myeloma.pdf
Multiple Myeloma.pdf
DelveInsight Business Research
 
What is the Common Warts.pdf
What is the Common Warts.pdfWhat is the Common Warts.pdf
What is the Common Warts.pdf
DelveInsight Business Research
 
Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expresse...
Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expresse...Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expresse...
Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expresse...
DelveInsight Business Research
 
GSK's Jemperli.pdf
GSK's Jemperli.pdfGSK's Jemperli.pdf
GSK's Jemperli.pdf
DelveInsight Business Research
 

More from DelveInsight Business Research (20)

BBXPB3422J_PARTB_2022-23 - Yashveer Bhardwaj.pdf
BBXPB3422J_PARTB_2022-23 - Yashveer Bhardwaj.pdfBBXPB3422J_PARTB_2022-23 - Yashveer Bhardwaj.pdf
BBXPB3422J_PARTB_2022-23 - Yashveer Bhardwaj.pdf
 
BBXPB3422J_2022- Yashveer Bhardwaj.pdf
BBXPB3422J_2022- Yashveer Bhardwaj.pdfBBXPB3422J_2022- Yashveer Bhardwaj.pdf
BBXPB3422J_2022- Yashveer Bhardwaj.pdf
 
Roche’s Glofitamab.pdf
Roche’s Glofitamab.pdfRoche’s Glofitamab.pdf
Roche’s Glofitamab.pdf
 
Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/...
Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/...Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/...
Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/...
 
Daiichi’s Patritumab.pdf
Daiichi’s Patritumab.pdfDaiichi’s Patritumab.pdf
Daiichi’s Patritumab.pdf
 
Enhertu carving out a new space for itself in HER2 low patients
 Enhertu carving out a new space for itself in HER2 low patients Enhertu carving out a new space for itself in HER2 low patients
Enhertu carving out a new space for itself in HER2 low patients
 
ASCO 2022 Conference.pdf
ASCO 2022 Conference.pdfASCO 2022 Conference.pdf
ASCO 2022 Conference.pdf
 
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its prom...
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its prom...Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its prom...
Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its prom...
 
Vasomotor Symptoms Infographic PDF.pdf
Vasomotor Symptoms Infographic PDF.pdfVasomotor Symptoms Infographic PDF.pdf
Vasomotor Symptoms Infographic PDF.pdf
 
Primary Hyperoxaluria
Primary HyperoxaluriaPrimary Hyperoxaluria
Primary Hyperoxaluria
 
ASCO CONFERENCE.Making Way For Immunotherapy In The GI Cancers, Durvalumab To...
ASCO CONFERENCE.Making Way For Immunotherapy In The GI Cancers, Durvalumab To...ASCO CONFERENCE.Making Way For Immunotherapy In The GI Cancers, Durvalumab To...
ASCO CONFERENCE.Making Way For Immunotherapy In The GI Cancers, Durvalumab To...
 
Chronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease MarketChronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease Market
 
Is there enough opportunity in the competitive therapeutic landscape of Multi...
Is there enough opportunity in the competitive therapeutic landscape of Multi...Is there enough opportunity in the competitive therapeutic landscape of Multi...
Is there enough opportunity in the competitive therapeutic landscape of Multi...
 
AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses ...
AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses ...AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses ...
AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses ...
 
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post succes...
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post succes...Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post succes...
Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post succes...
 
What is the Multiple Sclerosis.pdf
What is the Multiple Sclerosis.pdfWhat is the Multiple Sclerosis.pdf
What is the Multiple Sclerosis.pdf
 
Multiple Myeloma.pdf
Multiple Myeloma.pdfMultiple Myeloma.pdf
Multiple Myeloma.pdf
 
What is the Common Warts.pdf
What is the Common Warts.pdfWhat is the Common Warts.pdf
What is the Common Warts.pdf
 
Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expresse...
Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expresse...Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expresse...
Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expresse...
 
GSK's Jemperli.pdf
GSK's Jemperli.pdfGSK's Jemperli.pdf
GSK's Jemperli.pdf
 

Recently uploaded

Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
The Lifesciences Magazine
 
CANSA support - Caring for Cancer Patients' Caregivers
CANSA support - Caring for Cancer Patients' CaregiversCANSA support - Caring for Cancer Patients' Caregivers
CANSA support - Caring for Cancer Patients' Caregivers
CANSA The Cancer Association of South Africa
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Health Catalyst
 
CCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer RehabpptxCCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer Rehabpptx
Canadian Cancer Survivor Network
 
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareLGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
VITASAuthor
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
Naeemshahzad51
 
The positive impact of SGRT – The Berkshire Cancer Centre experience
The positive impact of SGRT – The Berkshire Cancer Centre experienceThe positive impact of SGRT – The Berkshire Cancer Centre experience
The positive impact of SGRT – The Berkshire Cancer Centre experience
SGRT Community
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
Rommel Luis III Israel
 
Nursing education curriculum development.pptx
Nursing education curriculum development.pptxNursing education curriculum development.pptx
Nursing education curriculum development.pptx
sadhanajagtap3
 
Rate Controlled Drug Delivery Systems.pdf
Rate Controlled Drug Delivery Systems.pdfRate Controlled Drug Delivery Systems.pdf
Rate Controlled Drug Delivery Systems.pdf
Rajarambapu College of Pharmacy Kasegaon Dist Sangli
 
Professional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine LectureProfessional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine Lecture
DIVYANSHU740006
 
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGYTime line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
DianaRodriguez639773
 
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdfChampions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
eurohealthleaders
 
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhfOne Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
AbdulMunim54
 
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
blessyjannu21
 
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DR Jag Mohan Prajapati
 
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
rowala30
 
定制(wsu毕业证书)美国华盛顿州立大学毕业证学位证书实拍图原版一模一样
定制(wsu毕业证书)美国华盛顿州立大学毕业证学位证书实拍图原版一模一样定制(wsu毕业证书)美国华盛顿州立大学毕业证学位证书实拍图原版一模一样
定制(wsu毕业证书)美国华盛顿州立大学毕业证学位证书实拍图原版一模一样
khvdq584
 
Bringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured ApproachBringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured Approach
Brian Frerichs
 
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
o6ov5dqmf
 

Recently uploaded (20)

Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...
 
CANSA support - Caring for Cancer Patients' Caregivers
CANSA support - Caring for Cancer Patients' CaregiversCANSA support - Caring for Cancer Patients' Caregivers
CANSA support - Caring for Cancer Patients' Caregivers
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
 
CCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer RehabpptxCCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer Rehabpptx
 
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareLGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
 
The positive impact of SGRT – The Berkshire Cancer Centre experience
The positive impact of SGRT – The Berkshire Cancer Centre experienceThe positive impact of SGRT – The Berkshire Cancer Centre experience
The positive impact of SGRT – The Berkshire Cancer Centre experience
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
 
Nursing education curriculum development.pptx
Nursing education curriculum development.pptxNursing education curriculum development.pptx
Nursing education curriculum development.pptx
 
Rate Controlled Drug Delivery Systems.pdf
Rate Controlled Drug Delivery Systems.pdfRate Controlled Drug Delivery Systems.pdf
Rate Controlled Drug Delivery Systems.pdf
 
Professional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine LectureProfessional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine Lecture
 
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGYTime line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
Time line.ppQAWSDRFTGYUIOPÑLKIUYTREWASDFTGY
 
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdfChampions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
 
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhfOne Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
 
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)
 
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
 
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
 
定制(wsu毕业证书)美国华盛顿州立大学毕业证学位证书实拍图原版一模一样
定制(wsu毕业证书)美国华盛顿州立大学毕业证学位证书实拍图原版一模一样定制(wsu毕业证书)美国华盛顿州立大学毕业证学位证书实拍图原版一模一样
定制(wsu毕业证书)美国华盛顿州立大学毕业证学位证书实拍图原版一模一样
 
Bringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured ApproachBringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured Approach
 
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
 

Type 1 diabetes ppt

  • 1. Type 1 Diabetes Presented by- DelveInsight Business Research
  • 2.
  • 3. What is Type 1 Diabetes? Diabetes is a chronic metabolic condition characterized by high or low blood glucose (or blood sugar) levels, leading to significant damage to the heart, blood vessels, eyes, kidneys, and nerves over time. The rationale behind developing diabetes incorporates two factors: insufficient insulin production (produced by the pancreas and reduced blood glucose) or unsatisfactory cell response to insulin action.
  • 4. Clinically, diabetes is classified into three types, type 1 diabetes (TD-1), Type 1 Diabetes (TD2), and gestation diabetes. TD1 is the consequence of an autoimmune reaction that causes the pancreas to suppress insulin-producing β-cells and leads to a severe insulin deficiency.
  • 5. TD2 is linked with a genetic factor, which is far more common and substantially correlates with obesity and unhealthy lifestyles. Insulin resistance (inadequate reaction of peripheral cells to insulin) and pancreatic β-cell dysfunction (impaired insulin secretion) are marked by Type 1 Diabetes, leading to relative insulin deficiency. View– Type 1 Diabetes market insights
  • 6. ● The US ● EU5 (Germany, France, Italy, Spain, and the United Kingdom) ● Japan How Many Regions Are Covered?
  • 7. This segment of the report provides a brief competitive analysis of Type 1 Diabetes, to help understand the competition in the market. It gives a comparative understanding of the products based on types of wounds.
  • 8. Type 1 diabetes is an autoimmune disorder, it is the most common type of diabetes among children, and however, type 1 diabetes can occur at any age. The typical symptoms of type 1 diabetes include excessive thirst, blurred vision, dry mouth, upset stomach and vomiting, bedwetting, frequent urination, unexplained weight loss, fatigue, labored breathing, lack of energy, and constant hunger. In patients having extreme type 1 diabetes, the symptoms include fruity odor to the breath, belly pain, and rapid breathing.
  • 9. The cause of type 1 diabetes is unknown, however since it is an autoimmune disorder, wherein the body mistakenly attacks the insulin-producing (islet, or islets of Langerhans) cells in the pancreas, other causes include; genetics and exposure to viruses and other environmental factors.
  • 10. The diagnostic procedure to confirm type 1 diabetes includes Glycated hemoglobin (A1C) test (> 6.5 on two separate tests, Random blood sugar test (> 200 mg/dL, along with symptoms of diabetes), Fasting blood sugar test(> 126 mg/dL on two separate tests). If the patient is diagnosed with diabetes, the doctor checks the presence of autoantibodies using blood tests.
  • 11. Focusing on the chronic and severe nature of type 1 diabetes and type 2 diabetes, the treatment approach for them is quite comprehensive; regularization of glucose metabolism (continuous use of insulin) and control of risk factors are the key treatment targets for type 1 diabetes. Also, read– Type 1 Diabetes treatment market
  • 12. What is the Type 1 Diabetes Market Report Scope? ● The report covers the descriptive overview of Type 1 Diabetes , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies ● Comprehensive insight has been provided into the Type 1 Diabetes epidemiology and treatment in the 7MM ● Additionally, an all-inclusive account of both the current and emerging therapies for Type 1 Diabetes are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape ● A detailed review of Type 1 Diabetes market; historical and forecasted is included in the report, covering drug outreach in the 7MM ● The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Type 1 Diabetes market
  • 13. What are the Type 1 Diabetes Market Report Highlights? ● In the coming years, Type 1 Diabetes market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market ● The companies and academics are working to assess challenges and seek opportunities that could influence Type 1 Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition ● Major players are involved in developing therapies for Type 1 Diabetes . Launch of emerging therapies will significantly impact the Type 1 Diabetes market ● A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Type 1 Diabetes
  • 14. CREDITS: This presentation template was created by Slidesgo, including icons by Flaticon, and infographics & images by Freepik Please keep this slide for attribution info@delveinsight.com ybhardwaj@delveinsight.com +91-9650213330 Do You Have Any Question or Query?
  • 15. CREDITS: This presentation template was created by Slidesgo, including icons by Flaticon, and infographics & images by Freepik Thanks!